Pulmonic Valvular Stenosis

Back

Background

Pulmonic valvular stenosis (PVS) is a form of right ventricular outflow tract obstruction (RVOTO). Stenosis may be valvular, subvalvular, or supravalvular. It is usually an isolated lesion and occurs in up to 12% of congenital heart disease (CHD).[1, 2] It is the most common cause of RVOTO.

Clinically relevant disease is typically diagnosed within the first year of life. Neonates with critical stenosis may present initially with central cyanosis at birth. Infants and children with ejection murmurs auscultated in the pulmonic region often undergo evaluation and PVS may be uncovered. PVS has been seen in the setting of well-defined congenital syndromes, most notably Holt-Oram syndrome, Noonan syndrome, and Leopard syndrome.[3, 4, 5] Eisenmenger syndrome associated with trisomy 13 also results in RVOTO in conjunction with other cardiac malformations.[6]

A large study called the Second Natural History Study of Congenital Heart Defects analyzed the treatment, quality of life, echocardiography findings, complications, exercise responses, and predisposition to endocarditis with regards to cardiac valvular disease, and pulmonary stenosis was found to be the most benign valvular lesion.[7]

According to the current ACC/AHA guidelines, PVS severity is defined by peak gradient across the pulmonic valve (PV), as follows[2] :

Disease course, outcomes and management are determined based on the illness severity.

Pathophysiology

Current guidelines outline the following three clinically relevant valve morphologies[2] :

Dome-shaped PV is more common, characterized by a narrow central opening with a preserved, mobile valve mechanism. Well-defined valve commissures are not present; however the structures exist in a rudimentary form. The pulmonary trunk may be dilated.[8, 9, 2]

Dysplastic PV is characterized by poorly mobile and myxomatous leaflets with no defined commissures. The pulmonary annulus and the right ventricular outflow tract (RVOT) may be narrowed as well. While uncommon, it is the typical morphology characteristic of Noonan syndrome.[8, 2]

The inheritance rate is low, although when part of Noonan syndrome it is autosomal dominant.[10] Mutations in germlines PTPN1 and RAF1 associated tetralogy of Fallot (TOF) are also associated with a uni- or bicuspid pulmonic valve, which may or may not cause an independent obstruction. Supravalvular lesions may occur in the setting of TOF, Williams syndrome, and Alagille syndrome, as well as in Noonan syndrome.[11]

During early development, the myocardial cushion begins as a matrix of endothelial cells and an outer mitochondrial layer separated by cardiac jelly. After endocardial cushion formation, the endothelial mesenchymal transformation (EMT), which are specified endothelial cells, differentiate and migrate into the cardiac jelly. Through a poorly understood process, the cardiac jelly goes through local expansion and bolus swelling, and cardiac valves are formed. The aortic and pulmonic valves develop from the outflow tract of the endocardial cushion, also believed to have neural crest cell migration from the brachial crest during development.[3]

Research suggests that the vascular endothelial growth factor (VEGF), a pleiotropic factor, is responsible for signaling the development of the endocardial cushion. Hypoxia and glucose have regulatory effects on this factor. Infants born to hyperglycemic mothers have a significant increase in cardiovascular abnormalities.[12] There has been correlation between intrapartum hypoxic events and valvular disease. Additionally, numerous signaling molecules contribute to VEGF and EMT such as the ERB-B signaling in the cardiac jelly, transforming growth factor (TGF)/cadherin, and bone morphogenetic protein (BMP)/TGF-beta.[3]

The pulmonic valve develops between the 6th and 9th week of gestation. Normally, the pulmonic valve is formed from three swellings of subendocardial tissue called the semilunar valves. These tubercles develop around the orifice of the pulmonary tree. The swellings are normally hollowed out and reshaped to form the three thin-walled cusps of the pulmonic valve. In Noonan syndrome, tissue pad overgrowth within the sinuses interferes with the normal mobility and function of the valve.

While pulmonic valvular stenosis is primarily a congenital malformation, it may also occur as part of congenital rubella syndrome. The most common etiologies of acquired are carcinoid syndrome, rheumatic fever, and homograft dysfunction.[8]

Epidemiology

United States data

Approximately 5 out of 1000 infants are born with a congenital cardiac malformation.[3] Valvular defects are the most common type of cardiac malformation, accounting for 25% of all malformations involving the myocardium.[3] The prevalence of pulmonic valvular stenosis accounts for 7-10% of all CHD.[13]

Sixty percent of patients with Noonan syndrome are found to have some degree of pulmonic valvular stenosis.[4]

Sex- and age-related demographics

The male-to-female ratio of pulmonic valvular stenosis is approximately 1:1. There are no sex-related differences in outcomes.[14]

When pulmonic valvular stenosis is diagnosed before one year of age, it is considered a high risk group and patients must undergo close lifetime follow up, including connection to a regional CHD specialty center.[14]

Prognosis

Mild pulmonic valvular stenosis has a good overall prognosis and life expectancy.[7] Recent literature suggests that pulmonic valvular stenosis is associated with a five times increase in mortality, especially in individuals who have not undergone intervention.[14] There was also a higher mortality seen in patients diagnosed before age one year, suggesting more severe disease in cases detected earlier in life.

Years of stenosis can result in subendocardial hypertrophy causing significant right ventricular outflow tract obstruction (RVOTO), resulting in right ventricular pressure overload and pulmonary hypertension. As this process worsens, an asymptomatic adult becomes gradually symptomatic.[15, 16]

Patients with moderately severe-to-severe stenosis have clinically progressing disease. The survival rate for severe stenosis is 96%; however, mean follow-up over a period of 33 years suggests that 53% of patients required further intervention. Forty percent may have associated atrial or ventricular arrhythmias.[11, 15]

Morbidity/mortality

Valvular disease in general has high morbidity and mortality rates. However, isolated pulmonic valvular stenosis has been found to be the most benign.[7] In the United States, about 82,000 valvular replacements are performed per year.[3] Survival to adulthood is most common, as symptoms and extent of disease progress with time.[17]

Much of what is known about the morbidity and mortality of pulmonic valvular stenosis comes from the Natural History Study of Congenital Heart Defects and the Second Natural History Study of Congenital Heart Defects. The Natural History Study of Congenital Heart Defects included an initial cardiac catheterization and then follow up for events over an 8-year period. The Second Natural History Study of Congenital Heart Defects reported on 16-27 years of follow up from the same cohort.[7]

The studies demonstrated that adverse outcomes directly relate to the right ventricular systolic pressure gradient.[18] Mild pulmonic valvular stenosis with pressure gradient across the valve less than 50 mm Hg was found to be well tolerated clinically and subjectively.[7] Of these patients, 94% were asymptomatic, without cyanosis or congestive heart failure (CHF).[19, 20] Moderate-to-severe pulmonic valvular stenosis, with pressure gradient greater than 50 mm Hg was more often associated with decreased cardiac output, right ventricular hypertrophy, early CHF, and cyanosis. Valvotomy has been shown to improve morbidity and mortality and is indicated in severe disease.[7]

The morbidity and mortality of valvular lesions in regard to pregnancy and fetal outcomes has not been rigorously studied. Recent literature suggests there is no impact of pulmonic valvular stenosis on maternal or fetal health.[21, 14]

Complications

Complications are rare and are mostly related to post valve repair (valvulotomy vs surgical).

In the unoperated patient with mild pulmonic valvular stenosis, disease is rarely progressive, owing to the mild gradient of flow.

Moderate and severe pulmonic valvular stenosis can progress to right heart failure, secondary to hypertrophy of the RVOT over time.[8, 2]

Patient Education

Patients and parents of those with mild PVS should be reassured that this condition is not related to, or associated with, coronary artery disease or sudden death. There is a mild association with benign dysrhythmia.[8, 7]

If the patient is asymptomatic with mild pulmonic valvular stenosis, an annual screening examination and ECG should be scheduled. Follow up every 3-5 years may be initiated if subsequent evaluations show no change.[11] Recent European Society of Cardiology (ESC) guidelines recommend that all patients, regardless of disease severity, should be seen by a specialist at least once in their lifetime. Mild disease can be followed routinely by a generalist or by a general cardiologist.[22]

History

Pulmonic valvular stenosis (PVS) in adults may present as an asymptomatic systolic murmur, or they may complain of decreased exercise tolerance.

In a functional and hemodynamic study of 19 Belgian patients with isolated mild-to-moderate pulmonary valve stenosis but no previous cardiac interventions, investigators reported significant differences in the following at-rest and exertional parameters between patients and their age- and sex-matched controls[23] :

The investigators indicated an observed linear increase in the peak pulmonary valve gradient may suggest a fixed valve area during exercise.[23] They also reported no signs of right heart functional or morphologic changes during exercise, with good ventricular performance.

Physical Examination

For most adults with pulmonic valvular stenosis (PVS), there are no classic phenotypic findings, and disease is suspected during cardiac examination.

For suspected Noonan syndrome, phenotypes include the following:

Cardiac examination findings correlate with the severity of stenosis, valve pathology, and other associated cardiac lesions. Rarely, overt right heart failure is seen (unless end-stage disease).

On auscultation, the first heart sound is normal and followed by a systolic ejection click loudest over the left upper sternal border.[11, 15] The murmur decreases with inspiration; this is secondary to the premature opening of the pulmonary valve by the atrial kick into a stiff right ventricle.[2]

The second heart sound may have a wide split, especially in severe disease. This is due to delayed closing of the pulmonic valve at the end of systole. The pulmonic component of the second heart sound may be diminished in intensity, and a right sided fourth heart sound may be heard.

In more severe pulmonic valvular stenosis, a right ventricular lift with associated jugular venous distention may be appreciated, and the pulmonary ejection murmur is much louder and longer.

Myocardial infarction of hypertrophied right ventricle may occur.[9] Cyanosis may occur with right-to-left shunting at the atrial level as with a patent foramen ovale or septal defect.[15]

Approach Considerations

Laboratory evaluation usually is not helpful.

Oximetry provides information on possible right-to-left shunting in borderline cyanotic lesions or in patients with anemia but does not identify the cause of the shunt (pulmonary, interatrial, interventricular, great arterial).[15]

Although arterial blood gases (ABG) analysis usually is not needed, one notable exception is the hyperoxia test in newborns with cyanosis of undetermined origin.

Administered 100% FIO2 generally does not increase the partial pressure of oxygen to levels much greater than 100 mm Hg in patients with a cyanotic congenital heart defect.

Electrocardiography is not diagnostic, and in mild to moderate pulmonic valvular stenosis will yield normal results. In severe pulmonic valvular stenosis, right axis deviation and right ventricular hypertrophy may occur.

According to the American College of Cardiology/American Heart Association guidelines for the management of adults with congenital heart disease, cardiac catheterization is unnecessary for diagnosis and should only be utilized when percutaneous catheter intervention is considered.[2]

Imaging Studies

Chest radiography

Chest radiography may demonstrate a prominent main pulmonary artery segment but a normal heart size; however, it may also present as congestive heart failure (CHF), with cardiomegaly secondary to enlarged right atria and ventricle.

Computed tomography scanning and magnetic resonance imaging

Modalities such as computed tomography (CT) scanning and magnetic resonance imaging (MRI) can show structural cardiac abnormalities.[24, 25] They are the preferred modality when echocardiogram cannot be used.

One case report described the identification of a patient with isolated subvalvular pulmonary stenosis using whole-heart MRI.[26] This imaging tool is noninvasive and has the added benefit of creating a 3-dimensional representation of the heart and surrounding structures. Other reports have described the use of whole-heart MRI as a presurgical adjunct.[24]

Cardiac CT has been beneficial for noninvasive presurgical evaluation of someone with known coronary artery disease. The radiation exposure is minimal, and the reconstructions of a 64-slice CT can yield very accurate images of myocardium changes associated with outflow tract obstruction.[25]

Echocardiography

Echocardiography is safer and more effective in the diagnosis of pulmonic valvular stenosis (PVS) compared with cardiac catheterization. It can determine flow gradients across the pulmonic valve, which is an indicator of disease severity.[7] Multiple views and measurements increase the accuracy. Additionally, in the parasternal short axis view, "doming" can be seen, which is evidence of a thickened pulmonic valve with restricted systolic motion.

The transthoracic approach provides valuable information about the site of obstruction and other possible congenital abnormalities.[18, 27, 28, 29] The transesophageal approach can also be used if the views are suboptimal, or if assessing for infective endocarditis.[2] Practice guidelines use echocardiography to determine definitive management in pulmonic valvular stenosis and as part of patient follow up.[30]

In a study that compared live/real-time three-dimensional transesophageal echocardiography (3D-TEE) with two-dimensional transesophageal echocardiography (2D-TEE) to determine whether there are advantages to using 3D-TEE on patients with pulmonary stenosis, investigators prospectively enrolled 16 consecutive adult patients with pulmonary stenosis and indications of TEE. They found evidence of the incremental value of using 3D-TEE instead of 2D-TEE during assessments of pulmonary stenosis, specifically in cases where special conditions cause inaccuracy in recordings of the transvalvular peak gradient. The investigators concluded that during routine echocardiographic examinations, 3D-TEE should be used as a complementary imaging tool to 2D-TEE.[31]

Most children with pulmonary stenosis do not require further evaluation beyond echocardiography.

Approach Considerations

Surgical management is the definitive treatment for pulmonic valvular stenosis (PVS). Patients with congestive heart failure may benefit from anticongestive therapy.

Interventions for pulmonic valvular stenosis include balloon dilatation, stenting, and pulmonic valve replacement.[32, 33, 34, 35]

Current guidelines recommend balloon valvuloplasty as the treatment of choice for all patients who can anatomically undergo the procedure.[22, 30] The American Heart Association (AHA) and American College of Cardiology (ACC) have established the following criteria[30] :

When surgical valve repair is required, it is typically in the setting of severe stenosis along with concomitant severe pulmonary regurgitation, hypoplastic annulus, subvalvular or supravalvular stenosis, or in a patient with dysplastic valves. Additionally, it may be considered when the patient is already undergoing a concurrent cardiac surgery.

Outcomes after balloon or surgical valvulotomy are generally excellent. Stenosis usually does not recur, and right ventricular hypertrophy often regresses.[11] A 2007 study presented long-term follow-up data on 90 adult patients who had pulmonary balloon valvuloplasty. Outcome data was excellent, and the study supports the use of balloon angioplasty.[36]

Prehospital Care

Oxygen should be administered to any patient in respiratory distress. Oxygen may also assist with pulmonary artery vasodilation, thus increasing pulmonary blood flow. Use of oxygen may reduce pulmonary artery pressure in patients with a reactive pulmonary vasculature, thus increasing pulmonary blood flow.

Emergency Department Care

Clinical evaluation and echocardiography will direct management. Patients presenting in extremis will need rapid stabilization, and it is recommended that transfer to a regional congenital heart disease center is initiated.[2]

Hospitalization

Intervention with either balloon angioplasty or valve repair is indicated for patients with severe or symptomatic infundibular or supravalvular pulmonic valvular stenosis (PVS). This is seen clinically with peak valve gradients more than 50 mm Hg, or for patients experiencing angina, presyncope, syncope, or exertional dyspnea. Corrective options include open heart surgery, balloon angioplasty, percutaneous stenting, percutaneous valve replacement, or percutaneous conduit placement.[11]

In infants, critical pulmonic valvular stenosis may present with near pulmonary atresia (a cyanotic lesion) with a small and often inadequate right ventricle. These patients survive because of a patent ductus arteriosus. Pulmonary valve atresia or critical pulmonic valvular stenosis with inadequate right ventricle requires a shunt (usually modified Blalock-Taussig or central shunt) after the ductus is kept patent pharmacologically with prostaglandin E1.[11] Definitive repair may not be possible if the right ventricle is hypoplastic, requiring a single ventricular palliation, such as the Fontan procedure, or a variation, such as a direct right atrial appendage to main pulmonary artery anastomosis.[17] Frequently, the main and branch pulmonary arteries require augmentation.

Patients with infundibular or supravalvular pulmonic stenosis, if severe, require operative and invasive surgical interventions.

A surgical approach is often preferred in patients with Noonan syndrome because of the degree of immobility that is often present.[37]

Patients who require such interventions should be transferred to a tertiary care center that specializes in congenital heart disease (CHD).

Complications

Postprocedure complications are rare. Infective endocarditis of the pulmonary valve is very rare. During the Second Natural History Study of Congenital Heart Defects, 592 patients with pulmonic valvular stenosis (PVS) were followed for 10,688 person-years; only one patient had an episode of bacterial endocarditis.[38] Current guidelines do not recommend for prophylaxis with antibiotics.[2]

Long-Term Monitoring

In the unoperated, asymptomatic patient with pulmonic valvular stenosis (PVS), ACC/AHA guidelines outline the following[2] :

Most patients with murmurs are given prophylaxis against infective subacute bacterial endocarditis (SBE).[39] Opinions differ about the need for SBE prophylaxis recommendations for patients with pulmonic valvular stenosis because of the extremely low incidence of endocarditis in this relatively large subpopulation.[39] Current ACC/AHA guidelines do not advise prophylaxis for pulmonic valvular stenosis.[2]

Author

Victoria Zaccone, MD, Resident Physician, Departments of Emergency Medicine and Internal Medicine, Kings County Hospital, SUNY Downstate Medical Center

Disclosure: Nothing to disclose.

Coauthor(s)

Bobak Zonnoor , MD, MMM, Assistant Professor of Emergency Medicine, SUNY Downstate School of Medicine; Director, ED Observation Unit, Department of Emergency Medicine, Kings County Hospital; Volunteer Assistant Clinical Professor, University of California, Los Angeles, David Geffen School of Medicine; Clinical Faculty, University of California, Riverside, School of Medicine

Disclosure: Nothing to disclose.

Specialty Editors

Francisco Talavera, PharmD, PhD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Chief Editor

Barry E Brenner, MD, PhD, FACEP, Program Director, Emergency Medicine, Einstein Medical Center Montgomery

Disclosure: Nothing to disclose.

Additional Contributors

David Eitel, MD, MBA, Associate Professor, Department of Emergency Medicine, York Hospital; Physician Advisor for Case Management, Wellspan Health System, York

Disclosure: Nothing to disclose.

Acknowledgements

Mert Erogul, MD Assistant Professor of Emergency Medicine, University Hospital of Brooklyn: Consulting Staff, Department of Emergency Medicine, Kings County Hospital Center

Mert Erogul, MD is a member of the following medical societies: American College of Emergency Physicians, American Medical Association, and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

Allysia M Guy, MD Staff Physician, Department of Emergency Medicine, State University of New York Downstate Medical Center

Disclosure: Nothing to disclose.

Kurt Pflieger, MD, FAAP Active Staff, Department of Pediatrics, Lake Pointe Medical Center

Kurt Pflieger, MD, FAAP is a member of the following medical societies: American Academy of Pediatrics, American College of Emergency Physicians, American Heart Association, and Texas Medical Association

Disclosure: Nothing to disclose.

David J Wallace, MD, MPH Resident, Assistant Professor of Clinical Medicine, Departments of Emergency Medicine and Internal Medicine, Kings County Hospital.

David J Wallace is a member of the following medical societies: Alpha Omega Alpha, American College of Emergency Physicians, American Medical Association, Emergency Medicine Residents Association, Society for Academic Emergency Medicine, and Society of Critical Care Medicine.

Disclosure: Nothing to disclose.

References

  1. Fyler DC. Pulmonary stenosis. Nadas Pediatric Cardiology. Philadelphia: Hanley and Belfus, Inc; 1992. 459-70.
  2. [Guideline] Warnes CA, Williams RG, Bashore TM, et al. ACC/AHA 2008 guidelines for the management of adults with congenital heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to develop guidelines for the management of adults with congenital heart disease). Circulation. 2008 Dec 2. 118(23):2395-451. [View Abstract]
  3. Armstrong EJ, Bischoff J. Heart valve development: endothelial cell signaling and differentiation. Circ Res. 2004 Sep 3. 95(5):459-70. [View Abstract]
  4. Hatemi AC, Gursoy M, Tongut A, et al. Pulmonary stenosis as a predisposing factor for infective endocarditis in a patient with Noonan syndrome. Tex Heart Inst J. 2010. 37(1):99-101. [View Abstract]
  5. Sarkozy A, Digilio MC, Dallapiccola B. Leopard syndrome. Orphanet J Rare Dis. 2008 May 27. 3:13. [View Abstract]
  6. Diller GP, van Eijl S, Okonko DO, et al. Circulating endothelial progenitor cells in patients with Eisenmenger syndrome and idiopathic pulmonary arterial hypertension. Circulation. 2008 Jun 10. 117(23):3020-30. [View Abstract]
  7. Nishimura RA, Gersony WM, et al. Second natural history study of congenital heart defects. Circulation. 1993 Feb. 87:89-137.
  8. Inglessis I, Landzberg MJ. Interventional catheterization in adult congenital heart disease. Circulation. 2007 Mar 27. 115(12):1622-33. [View Abstract]
  9. Moore KL, Persaud T. The cardiovascular system. The Developing Human: Clinically Oriented Embryology. 7th ed. Philadelphia: Saunders; 2005. 329-80.
  10. Jorge AA, Malaquias AC, Arnhold IJ, Mendonca BB. Noonan syndrome and related disorders: a review of clinical features and mutations in genes of the RAS/MAPK pathway. Horm Res. 2009. 71(4):185-93. [View Abstract]
  11. Libby P, Bonow RO, Mann DL, Zipes DP. Braunwald's Heart Disease; A Textbook of Cardiovascular Medicine. 8th ed. Saunders Inc; 2007.
  12. Al-Biltagi M, El Razaky O, El Amrousy D. Cardiac changes in infants of diabetic mothers. World J Diabetes. 2021 Aug 15. 12(8):1233-47. [View Abstract]
  13. Heaton J, Kyriakopoulos C. Pulmonic stenosis. StatPearls [Internet]. 2022 Jan. [View Abstract]
  14. Skoglund K, Rosengren A, Lappas G, Fedchenko M, Mandalenakis Z. Long-term survival in patients with isolated pulmonary valve stenosis: a not so benign disease?. Open Heart. 2021 Sep. 8(2):e001836. [View Abstract]
  15. Meyer TE, Tighe DA. Tricuspid and pulmonic valve disease. In: Crawford MH, DiMarco JP, Paulus WJ, eds. Cardiology: Expert Consult. 3rd ed. Philadelphia: Mosby Inc; 2009. 1315-20.
  16. Morjaria S, Grinnan D, Voelkel N. Massive dilatation of the pulmonary artery in association with pulmonic stenosis and pulmonary hypertension. Pulm Circ. 2012 Apr. 2(2):256-7. [View Abstract]
  17. Perloff JK, Child JS, Aboulhosn J. Pulmonic valvular disease. Congenital Heart Disease in Adults. 3rd ed. Philadelphia: Saunders; 2008.
  18. Nishimura RA, Pieroni DR, Bierman FZ, et al. Second natural history study of congenital heart defects. Pulmonary stenosis: echocardiography. Circulation. 1993 Feb. 87(2 Suppl):I73-9. [View Abstract]
  19. Driscoll DJ, Wolfe RR, Gersony WM, et al. Cardiorespiratory responses to exercise of patients with aortic stenosis, pulmonary stenosis, and ventricular septal defect. Circulation. 1993 Feb. 87(2 Suppl):I102-13. [View Abstract]
  20. Ardura J, Gonzalez C, Andres J. Does mild pulmonary stenosis progress during childhood? A study of its natural course. Clin Cardiol. 2004 Sep. 27(9):519-22. [View Abstract]
  21. Hameed AB, Goodwin TM, Elkayam U. Effect of pulmonary stenosis on pregnancy outcomes--a case-control study. Am Heart J. 2007 Nov. 154(5):852-4. [View Abstract]
  22. [Guideline] Baumgartner H, De Backer J, Babu-Narayan SV, et al, for the ESC Scientific Document Group. 2020 ESC Guidelines for the management of adult congenital heart disease. Eur Heart J. 2021 Feb 11. 42(6):563-645. [View Abstract]
  23. De Meester P, Buys R, Van De Bruaene A, et al. Functional and haemodynamic assessment of mild-to-moderate pulmonary valve stenosis at rest and during exercise. Heart. 2014 Sep. 100(17):1354-9. [View Abstract]
  24. Seibt C, Flender B, Gutberlet M. Comprehensive non-invasive pre-surgical magnetic resonance imaging in a patient with LEOPARD's syndrome cardiomyopathy. Eur Heart J. 2006 Jun. 27(12):1407. [View Abstract]
  25. Bettencourt N, Rocha J, Carvalho M, et al. Multislice computed tomography in the exclusion of coronary artery disease in patients with presurgical valve disease. Circ Cardiovasc Imaging. 2009 Jul. 2(4):306-13. [View Abstract]
  26. Sato Y, Komatsu S, Matsuo S, et al. Isolated subvalvular pulmonary stenosis: depiction at whole heart magnetic resonance imaging. Int J Cardiovasc Imaging. 2007 Feb. 23(1):49-52. [View Abstract]
  27. Silverman NH. Right heart obstructive lesions. Pediatric Echocardiography. Philadelphia: Lippincott Williams & Wilkins; 1993. 327.
  28. Snider AR, Serwer GA. Abnormalities to right ventricular outflow. Echocardiography in Pediatric Heart Disease. St Louis: Year Book Medical Publishers; 1990. 231-41.
  29. Kilner PJ. Imaging congenital heart disease in adults. Br J Radiol. 2011 Dec. 84(Spec Iss 3):S258-68. [View Abstract]
  30. [Guideline] Nishimura RA, Otto CM, Bonow RO, et al, for the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014 Jun 10. 63(22):e57-185. [View Abstract]
  31. Kemaloglu Oz T, Ozpamuk Karadeniz F, Akyuz S, et al. The advantages of live/real time three-dimensional transesophageal echocardiography during assessments of pulmonary stenosis. Int J Cardiovasc Imaging. 2016 Apr. 32(4):573-82. [View Abstract]
  32. Bonhoeffer P, Boudjemline Y, Qureshi SA, et al. Percutaneous insertion of the pulmonary valve. J Am Coll Cardiol. 2002 May 15. 39(10):1664-9. [View Abstract]
  33. Block PC, Bonhoeffer P. Percutaneous approaches to valvular heart disease. Curr Cardiol Rep. 2005 Mar. 7(2):108-13. [View Abstract]
  34. Violini R, Vairo U, Hijazi ZM. Stent strut breakage using high-pressure balloons for bifurcation stenting and subsequent percutaneous pulmonary valve replacement using the Edwards Sapien THV. Catheter Cardiovasc Interv. 2013 Nov 1. 82(5):834-7. [View Abstract]
  35. Roselli EE, Abdel Azim A, Houghtaling PL, Jaber WA, Blackstone EH. Pulmonary hypertension is associated with worse early and late outcomes after aortic valve replacement: implications for transcatheter aortic valve replacement. J Thorac Cardiovasc Surg. 2012 Nov 1. 144(5):1067-1074.e2. [View Abstract]
  36. Fawzy ME, Hassan W, Fadel BM, et al. Long-term results (up to 17 years) of pulmonary balloon valvuloplasty in adults and its effects on concomitant severe infundibular stenosis and tricuspid regurgitation. Am Heart J. 2007 Mar. 153(3):433-8. [View Abstract]
  37. Castaneda AR, Jonas RA, Meyer JE. Surgery for infants with congenital heart defects. Cardiac Surgery. 1993. 1013-35.
  38. Gersony WM, Hayes CJ, Driscoll DJ, et al. Bacterial endocarditis in patients with aortic stenosis, pulmonary stenosis, or ventricular septal defect. Circulation. 1993 Feb. 87(2 Suppl):I121-6. [View Abstract]
  39. [Guideline] Wilson W, Taubert KA, Gewitz M, et al. Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation. 2007 Oct 9. 116(15):1736-54. [View Abstract]
  40. Blount SG, Komesu S, McCord MC. Asymptomatic isolated valvular pulmonary stenosis; diagnosis by clinical methods. N Engl J Med. 1953 Jan 1. 248(1):5-11. [View Abstract]
  41. Driscoll DJ, Michels VV, Gersony WM, et al. Occurrence risk for congenital heart defects in relatives of patients with aortic stenosis, pulmonary stenosis, or ventricular septal defect. Circulation. 1993 Feb. 87(2 Suppl):I114-20. [View Abstract]
  42. Kula S, Saygili A, Tunaoglu FS, Olgunturk R. Mayer-Rokitansky-Küster-Hauser syndrome associated with pulmonary stenosis. Acta Paediatr. 2004 Apr. 93(4):570-2. [View Abstract]
  43. Wolfe RR, Driscoll DJ, Gersony WM, et al. Arrhythmias in patients with valvar aortic stenosis, valvar pulmonary stenosis, and ventricular septal defect. Results of 24-hour ECG monitoring. Circulation. 1993 Feb. 87(2 Suppl):I89-101. [View Abstract]
  44. Kan JS, White RI Jr, Mitchell SE, Gardner TJ. Percutaneous balloon valvuloplasty: a new method for treating congenital pulmonary-valve stenosis. N Engl J Med. 1982 Aug 26. 307(9):540-2. [View Abstract]
  45. Liu S, Xu X, Liu G, Ding X, Zhao X, Qin Y. Comparison of immediate and long-term results between the single balloon and inoue balloon techniques for percutaneous pulmonary valvuloplasty. Heart Lung Circ. 2015 Jan. 24(1):40-5. [View Abstract]
  46. Galal MO, Jadoon S, Momenah TS. Pulmonary valvuloplasty in a pregnant woman using sole transthoracic echo guidance: technical considerations. Can J Cardiol. 2015 Jan. 31(1):103.e5-7. [View Abstract]
  47. Drenthen W, Boersma E, Balci A, et al, for the ZAHARA Investigators. Predictors of pregnancy complications in women with congenital heart disease. Eur Heart J. 2010 Sep. 31(17):2124-32. [View Abstract]
  48. Roos-Hesselink JW, Meijboom FJ, Spitaels SE, et al. Long-term outcome after surgery for pulmonary stenosis (a longitudinal study of 22-33 years). Eur Heart J. 2006 Feb. 27(4):482-8. [View Abstract]
  49. Ruckdeschel ES, Schuller J, Nguyen DT. Ventricular tachycardia in congenital pulmonary stenosis. Card Electrophysiol Clin. 2016 Mar. 8(1):205-9. [View Abstract]
  50. Kokkinidis DG, Papanastasiou CA, Jonnalagadda AK, et al. The predictive value of baseline pulmonary hypertension in early and long term cardiac and all-cause mortality after transcatheter aortic valve implantation for patients with severe aortic valve stenosis: a systematic review and meta-analysis. Cardiovasc Revasc Med. 2018 Oct-Nov. 19(7 Pt B):859-67. [View Abstract]
  51. Lyon SM, Ofner S, Cheng P, et al. Serial magnetic resonance imaging for aortic dilation in tetralogy of Fallot with pulmonary stenosis. Am J Cardiol. 2023 Mar 15. 191:92-100. [View Abstract]